Patents by Inventor Sandra Zurawski

Sandra Zurawski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240131138
    Abstract: Chlamydiae are intracellular bacterial pathogens responsible for a variety of infections. The inventors produced an antibody that is directed against a surface antigen (i.e., CD40) of an antigen presenting cell (i.e., dendritic cell) wherein the heavy chain and/or light chain is conjugated to the MOMP VS4 domain of Chlamydia trachomatis for its use as vaccine.
    Type: Application
    Filed: December 22, 2021
    Publication date: April 25, 2024
    Applicants: Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance Publique - Hopitaux de Paris (APHP), Baylor Research Institute, Universite Paris Est Creteil Val De Marne
    Inventors: Yves LEVY, Sylvain CARDINAUD, Mireille CENTLIVRE, Lydie DIEUDONNE, Sandra ZURAWSKI, Gérard ZURAWSKI
  • Publication number: 20240124532
    Abstract: Chlamydiae are intracellular bacterial pathogens responsible for a variety of infections. The inventors have set up candidate vaccines against Chlamydia trachomatis. In particular, the inventors have identified specific epitopes to be included in vaccine candidates thanks to in silico analysis of the amino-acid sequence of these proteins to map predicted MHC-I and -II epitopes by online software (NetMHC-4.0 and NetMHCII-2.3) and peptide binding prediction software. B cell epitopes were also mapped using online software (BepiPred-2.0 and Discotope). Finally, the inventors have generated some specific CD40 or Langerin antibodies comprising one or more identified epitope(s) of the present invention and that are suitable for vaccine purposes. Therefore, the present invention relates to Chlamydia trachomatis (Ct) antigenic polypeptides and uses thereof for vaccine purposes.
    Type: Application
    Filed: January 28, 2022
    Publication date: April 18, 2024
    Applicants: Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance Publique - Hopitaux de Paris, Universite Paris Est Creteil Val De Marne, Baylor Research Institute
    Inventors: Yves LEVY, Sandra ZURAWSKI, Gérard ZURAWSKI, Mireille CENTLIVRE, Lydie DIEUDONNE, Sylvain CARDINAUD
  • Patent number: 11957734
    Abstract: Described herein are compositions and methods for inhibiting an inflammatory or autoimmune response and for inducing immune tolerance in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an antigen presenting cell (APC)-targeted antibody operatively linked to IL-10 or a fragment thereof. The compositions and methods described herein are useful for treating inflammatory and autoimmune disorders.
    Type: Grant
    Filed: March 25, 2021
    Date of Patent: April 16, 2024
    Assignee: Baylor Research Institute
    Inventors: SangKon Oh, Sandra Zurawski, Hyemee Joo, Gerard Zurawski
  • Publication number: 20240033340
    Abstract: Embodiments relate to novel vaccines against human papillomavirus (HPV) and HPV-related diseases, including multiple types of cancers. The HPV vaccines are composed of anti-human dendritic cell (DC) surface receptor antibodies, including CD40, and E6/7 proteins of HPV16 and 18. The technology described is not limited to making vaccines against HPV16- and HPV18-related diseases and can be applied to making vaccines carrying E6/7 from any type of HPV. The HPV vaccines described can target DCs, major and professional antigen presenting cells (APCs), and can induce and activate potent HPV E6/7-specific and strong CD4+ and CD8+ T cell responses. The HPV vaccines can be used for the prevention of HPV infection and HPV-related diseases as well as for the treatment of HPV-related diseases, including cancers.
    Type: Application
    Filed: June 6, 2023
    Publication date: February 1, 2024
    Applicant: BAYLOR RESEARCH INSTITUTE
    Inventors: SangKon OH, Sandra ZURAWSKI, Gerard ZURAWSKI
  • Publication number: 20240010739
    Abstract: SARS-CoV-2 vaccines will be essential to reduce morbidity and mortality. The inventors produced an antibody that is directed against a surface antigen (i.e. CD40) of an antigen presenting cell (i.e. dendritic cell) wherein the heavy chain was conjugated to the receptor-binding domain of the Sars-Cov-2 spike protein for its use as vaccine. In particular, the inventors show that said vaccine induces circulating Ab-secreting hu-B cells, elicits S-specific IgG+ hu-B cells, elicits the expansion of central memory CD4+ hu-T cells and the emergence of effector memory CD4+ T cells, elicits the expansion of central memory CD8+ hu-T cells at and the emergence of effector memory CD8+ T cells at and finally induces Stem-cell like memory hu-CD8+ T cells.
    Type: Application
    Filed: November 10, 2021
    Publication date: January 11, 2024
    Applicants: Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance Publique - Hopitaux de Paris (APHP), Baylor Research Institute, Universite Paris Est Creteil Val De Marne
    Inventors: Yves LEVY, Gérard ZURAWSKI, Mireille CENTLIVRE, Sandra ZURAWSKI, Véronique GODOT
  • Patent number: 11806390
    Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.
    Type: Grant
    Filed: April 12, 2021
    Date of Patent: November 7, 2023
    Assignee: BAYLOR RESEARCH INSTITUTE
    Inventors: Gerard Zurawski, Jacques F. Banchereau, Anne-Laure Flamar, Peter Klucar, Keiko Akagawa, Sandra Zurawski, SangKon Oh
  • Patent number: 11717567
    Abstract: Embodiments relate to novel vaccines against human papillomavirus (HPV) and HPV-related diseases, including multiple types of cancers. The HPV vaccines are composed of anti-human dendritic cell (DC) surface receptor antibodies, including CD40, and E6/7 proteins of HPV16 and 18. The technology described is not limited to making vaccines against HPV16- and HPV18-related diseases and can be applied to making vaccines carrying E6/7 from any type of HPV. The HPV vaccines described can target DCs, major and professional antigen presenting cells (APCs), and can induce and activate potent HPV E6/7-specific and strong CD4+ and CD8+ T cell responses. The HPV vaccines can be used for the prevention of HPV infection and HPV-related diseases as well as for the treatment of HPV-related diseases, including cancers.
    Type: Grant
    Filed: March 8, 2021
    Date of Patent: August 8, 2023
    Assignee: Baylor Research Institute
    Inventors: SangKon Oh, Sandra Zurawski, Gerard Zurawski
  • Publication number: 20230212231
    Abstract: The present disclosure provides polypeptides derived from SARS-CoV-2 which have therapeutic use. One such polypeptide is a polypeptide, referred to as “Npep2,” is derived from the SARS-CoV-2 protein N and has at least 50 consecutive amino acids of the amino acid sequence having at least 90% identity with the amino acid sequence that ranges from the residue at position 276 to the residue at position 411 of SEQ ID NO:2. Further described are conjugates wherein a heterologous polypeptide is conjugated or fused to Npep2. The present disclosure further provides vaccines employing the polypeptides, polynucleotides encoding the polypeptides, and methods of vaccinating subjects against SARS-CoV-2 by administering a therapeutically effective amount of one or more of the polypeptides.
    Type: Application
    Filed: May 26, 2021
    Publication date: July 6, 2023
    Applicants: Institut National de la Santé et de la Recherche Médicale (INSERM), Baylor Research Institute, Assistance Publique - Hopitaux de Paris (APHP), Universite Paris Est Creteil Val de Marne
    Inventors: Yves LEVY, Gérard ZURAWSKI, Sandra ZURAWSKI, Christine LACABARATZ, Sylvain CARDINAUD, Mathieu SURENAUD
  • Publication number: 20230183366
    Abstract: The disclosure relates to the field of OX40 activating proteins. More specifically, it is disclosed herein recombinant proteins with OX40 agonist antibodies or their antigen-binding fragments fused or linked to OX40 ligand. Also disclosed is the advantageous use of such OX40 activating proteins, in particular for inducing immune responses directed to delivered antigens such as viral or cancer antigens, and/or for treating cancer.
    Type: Application
    Filed: May 11, 2021
    Publication date: June 15, 2023
    Inventors: Yves LEVY, Sandra ZURAWSKI, Gérard ZURAWSKI
  • Publication number: 20230034677
    Abstract: The inventors now provide novel IL-15/IL-15 receptor alpha (IL-15R?) fusion proteins. Furthermore, as a complement to anti-PD-1 therapy, the inventors developed a series of anti-PD-1/IL-15/IL-15 receptor alpha (IL-15R?) immunocytokines that are able to simultaneously target multiple steps in the immune activation process. The development of said immunocytokines provides the potential benefits associated with anti-PD-1 antibodies and IL-15 administered individually with several distinct advantages. These include a significantly extended in vivo half-life relative to the IL-15 therapy, administration of a pre-formed IL-15/IL-15R? complex that would preclude the need for IL-15R? trans-presentation, high activity leading to a low target therapeutic dose and targeted delivery of IL-15 to regions with high PD-1 cells that will limit off-target adverse events.
    Type: Application
    Filed: November 20, 2020
    Publication date: February 2, 2023
    Inventors: Yves LEVY, Giuseppe PANTALEO, Craig FENWICK, Sandra ZURAWSKI, Gérard ZURAWSKI, Nabila SEDDIKI
  • Publication number: 20220340670
    Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccine and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.
    Type: Application
    Filed: March 7, 2022
    Publication date: October 27, 2022
    Inventors: Jacques F. Banchereau, Gerard Zurawski, Sandra Zurawski, SangKon Oh
  • Publication number: 20220175920
    Abstract: The disclosure relates to the field of CD40 activating proteins. More specifically, it is disclosed herein recombinant proteins with CD40 agonist antibodies or their antigen-binding fragments fused or linked to CD40 ligand. Also disclosed is the advantageous use of such CD40 activating proteins, in particular for inducing immune responses directed to delivered antigens such as viral or cancer antigens.
    Type: Application
    Filed: March 26, 2020
    Publication date: June 9, 2022
    Inventors: Yves LEVY, Valentina CEGLIA, Sandra ZURAWSKI, Gerard ZURAWSKI
  • Patent number: 11267895
    Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccine and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.
    Type: Grant
    Filed: June 15, 2020
    Date of Patent: March 8, 2022
    Assignee: Baylor Research Institute
    Inventors: Jacques F. Banchereau, Gerard Zurawski, Sandra Zurawski, SangKon Oh
  • Patent number: 11219683
    Abstract: Methods and compositions are provided that can be used to vaccinate against and treat HIV. Specifically contemplated are vaccine compositions and methods of using these compositions treat HIV in patients. Aspects of the disclosure relate to an anti-CD40 antibody-HIV antigen fusion protein comprising (i) an anti-CD40 heavy chain (HCD40)-HIV antigen (Ag) fusion protein comprising the formula: HCD40-Ag, wherein Ag is a polypeptide with at least 80% sequence identity to SEQ ID NO:1; and (ii) an anti-CD40 light chain (LCD40).
    Type: Grant
    Filed: June 19, 2020
    Date of Patent: January 11, 2022
    Assignees: INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE M{circumflex over (D)}DICALE (INSERM), UNIVERSITE PARIS EST CRETEIL VAL DE MARNE, ASSISTANCE PUBLIQUE HOPITAUX DE PARIS, BAYLOR RESEARCH INSTITUTE
    Inventors: Yves Levy, Gerard Zurawski, Sandra Zurawski, Anne-Laure Flamar
  • Publication number: 20210308242
    Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.
    Type: Application
    Filed: April 12, 2021
    Publication date: October 7, 2021
    Applicant: BAYLOR RESEARCH INSTITUTE
    Inventors: Gerard ZURAWSKI, Jacques F. Banchereau, Anne-Laure FLAMAR, Peter KLUCAR, Keiko AKAGAWA, Sandra ZURAWSKI, SangKon OH
  • Publication number: 20210299224
    Abstract: Described herein are compositions and methods for inhibiting an inflammatory or autoimmune response and for inducing immune tolerance in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an antigen presenting cell (APC)-targeted antibody operatively linked to IL-10 or a fragment thereof. The compositions and methods described herein are useful for treating inflammatory and autoimmune disorders.
    Type: Application
    Filed: March 25, 2021
    Publication date: September 30, 2021
    Applicant: BAYLOR RESEARCH INSTITUTE
    Inventors: SangKon OH, Sandra ZURAWSKI, Hyemee JOO, Gerard ZURAWSKI
  • Publication number: 20210268097
    Abstract: Embodiments relate to novel vaccines against human papillomavirus (HPV) and HPV-related diseases, including multiple types of cancers. The HPV vaccines are composed of anti-human dendritic cell (DC) surface receptor antibodies, including CD40, and E6/7 proteins of HPV16 and 18. The technology described is not limited to making vaccines against HPV16- and HPV18-related diseases and can be applied to making vaccines carrying E6/7 from any type of HPV. The HPV vaccines described can target DCs, major and professional antigen presenting cells (APCs), and can induce and activate potent HPV E6/7-specific and strong CD4+ and CD8+ T cell responses. The HPV vaccines can be used for the prevention of HPV infection and HPV-related diseases as well as for the treatment of HPV-related diseases, including cancers.
    Type: Application
    Filed: March 8, 2021
    Publication date: September 2, 2021
    Applicant: BAYLOR RESEARCH INSTITUTE
    Inventors: SangKon OH, Sandra ZURAWSKI, Gerard ZURAWSKI
  • Patent number: 10993990
    Abstract: Described herein are compositions and methods for inhibiting an inflammatory or autoimmune response and for inducing immune tolerance in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an antigen presenting cell (APC)-targeted antibody operatively linked to IL-10 or a fragment thereof. The compositions and methods described herein are useful for treating inflammatory and autoimmune disorders.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: May 4, 2021
    Assignee: Baylor Research Institute
    Inventors: SangKon Oh, Sandra Zurawski, Hyemee Joo, Gerard Zurawski
  • Patent number: 10980869
    Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: April 20, 2021
    Assignee: Baylor Research Institute
    Inventors: Gerard Zurawski, Jacques F. Banchereau, Anne-Laure Flamar, Peter Klucar, Keiko Akagawa, Sandra Zurawski, SangKon Oh
  • Patent number: 10940195
    Abstract: Embodiments relate to novel vaccines against human papillomavirus (HPV) and HPV-related diseases, including multiple types of cancers. The HPV vaccines are composed of anti-human dendritic cell (DC) surface receptor antibodies, including CD40, and E6/7 proteins of HPV16 and 18. The technology described is not limited to making vaccines against HPV16- and HPV18-related diseases and can be applied to making vaccines carrying E6/7 from any type of HPV. The HPV vaccines described can target DCs, major and professional antigen presenting cells (APCs), and can induce and activate potent HPV E6/7-specific and strong CD4+ and CD8+ T cell responses. The HPV vaccines can be used for the prevention of HPV infection and HPV-related diseases as well as for the treatment of HPV-related diseases, including cancers.
    Type: Grant
    Filed: April 29, 2019
    Date of Patent: March 9, 2021
    Assignee: Baylor Research Institute
    Inventors: SangKon Oh, Sandra Zurawski, Gerard Zurawski